Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Evommune (EVMN) EBT (2024 - 2025)

Evommune (EVMN) has disclosed EBT for 2 consecutive years, with -$28.3 million as the latest value for Q4 2025.

  • Quarterly EBT fell 36.41% to -$28.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$77.4 million through Dec 2025, changed N/A year-over-year, with the annual reading at -$77.8 million for FY2025, 16.45% down from the prior year.
  • EBT for Q4 2025 was -$28.3 million at Evommune, down from -$12.5 million in the prior quarter.
  • The five-year high for EBT was -$12.5 million in Q3 2025, with the low at -$28.3 million in Q4 2025.